SG Americas Securities LLC Trims Holdings in Illumina, Inc. (NASDAQ:ILMN)

SG Americas Securities LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 93.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,582 shares of the life sciences company’s stock after selling 22,245 shares during the quarter. SG Americas Securities LLC’s holdings in Illumina were worth $206,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Trivant Custom Portfolio Group LLC grew its position in Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the last quarter. Versant Capital Management Inc grew its position in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new position in Illumina during the 2nd quarter valued at about $34,000. Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. Finally, Itau Unibanco Holding S.A. bought a new position in Illumina during the 2nd quarter valued at about $61,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ILMN shares. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research note on Thursday, October 17th. Barclays increased their price objective on shares of Illumina from $125.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 15th. Piper Sandler lowered their price objective on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. UBS Group increased their price objective on shares of Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a research note on Wednesday, July 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $154.33.

Illumina Stock Down 0.8 %

Shares of ILMN opened at $144.06 on Wednesday. The company has a market cap of $22.95 billion, a PE ratio of -17.68 and a beta of 1.15. The business has a fifty day moving average of $133.63 and a 200 day moving average of $121.35. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $151.40. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the company earned $0.32 earnings per share. Illumina’s revenue was down 5.4% on a year-over-year basis. On average, sell-side analysts expect that Illumina, Inc. will post 3.63 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.